These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18091052)

  • 1. Obesity is not predictive of overall survival following permanent prostate brachytherapy.
    Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Adamovich E
    Am J Clin Oncol; 2007 Dec; 30(6):588-96. PubMed ID: 18091052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.
    Merrick GS; Galbreath RW; Butler WM; Waller KE; Allen ZA; Lief J; Adamovich E
    Cancer; 2007 Jul; 110(2):289-96. PubMed ID: 17549691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate brachytherapy in men > or =75 years of age.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Adamovich E
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):415-20. PubMed ID: 18374514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
    Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary causes of death after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
    Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Shetti MB; Merrick GS; Butler WM; Galbreath R; Torlone A; Lief JH; Adamovich E; Wallner KE
    Am J Clin Oncol; 2012 Dec; 35(6):572-9. PubMed ID: 22134514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1104-10. PubMed ID: 20864268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Lief JH; Adamovich E
    Am J Clin Oncol; 2008 Dec; 31(6):539-44. PubMed ID: 19060584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
    BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
    Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.